Zynerba Pharma rises as gel improves condition of neurological disorder patients

Zynerba Pharmaceuticals

26/05/2020 12:33

** Drug developer's shares  ZYNE.O  rise 8% to $7 premarket;
among top pct gainers across U.S. exchanges
    ** Co says data from two year long mid-stage study shows its
Cannabidiol gel, Zygel, sustained statistical improvements in
aberrant behavior in patients with neurological disorder-
Fragile X  urn:newsml:reuters.com:*:nGNX3Rcxsx
    ** The trial is testing the gel in pediatric and adolescent
patients with Fragile X syndrome- a genetic condition that
causes a range of developmental problems including learning
disabilities and cognitive impairment
    ** Stock up 7.3% YTD as of last close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))